<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543543</url>
  </required_header>
  <id_info>
    <org_study_id>V503-001</org_study_id>
    <secondary_id>2007_538</secondary_id>
    <nct_id>NCT00543543</nct_id>
  </id_info>
  <brief_title>Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)</brief_title>
  <official_title>A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of V503 in
      comparison to GARDASIL. The primary hypotheses tested in the study are 1) V503 administered
      to 16- to 26-year-old adolescents and young women is generally well-tolerated, 2) V503
      reduces combined incidence of Human Papillomavirus (HPV) Type 31/33/45/52/58-related disease
      compared with GARDASIL, and 3) V503 induces non-inferior geometric mean titers for HPV Type
      6/11/16/18 antibodies compared with GARDASIL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes a double-blind, dose-finding evaluation of a 3-dose regimen of 3 dose
      formulations of V503 and GARDASIL (Base Study Part A), a double-blind, safety/efficacy
      evaluation of a 3-dose regimen of the V503 dose formulation selected in Part A and GARDASIL
      (Base Study Part B), and an open-label extension consisting of 2 substudies: an evaluation
      of immune memory in participants receiving a fourth vaccination with V503 (Extension Cohort
      1) and an opportunity for participants who received GARDASIL in the base study to receive a
      3-dose regimen of V503 (Extension Cohort 2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis)</measure>
    <time_frame>From Day 1 until &gt;=30 cases accumulate, up to Month 54 in the base study</time_frame>
    <description>HPV Type 31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer were determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. This outcome measure reports data based on the protocol-specified plan of conducting hypothesis testing when at least 30 cases had accumulated. The cutoff date for this analysis was 10 April 2013. Disease incidence was defined as the number of primary efficacy cases per 10,000 person-years of follow-up in a treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (End-of-study Update)</measure>
    <time_frame>Up to Month 54 in the base study</time_frame>
    <description>HPV Type 31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer were determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. This outcome measure reports cumulative study data through 10 March 2014. Disease incidence was defined as the number of primary efficacy cases per 10,000 person-years of follow-up in a treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18/31/33/45/52/58</measure>
    <time_frame>4 weeks postdose 3 in the base study</time_frame>
    <description>Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. Statistical analysis was performed only for HPV types contained in both vaccines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extension Study: Geometric Mean Titers to HPV Types 6/11/16/18/31/33/45/52/58</measure>
    <time_frame>Day 7 and Day 28 postdose 4 in the extension study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With One or More Adverse Event</measure>
    <time_frame>Up to Month 7 (low- and high-dose V503) or up to Month 54 (mid-dose V503 and Gardasil)</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With One or More Injection-site Adverse Event</measure>
    <time_frame>Up to Day 5 after any vaccination</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With One or More Non-injection-site (Systemic) Adverse Event</measure>
    <time_frame>Up to Day 15 after any vaccination</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With One or More Vaccine-related Adverse Event</measure>
    <time_frame>Up to Month 7 (low- and high-dose V503) or up to Month 54 (mid-dose V503 and Gardasil)</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. An AE that is judged by the investigator to be &quot;definitely related,&quot; &quot;probably related,&quot; or &quot;possibly related&quot; to the study drug is defined as a vaccine-related AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base Study: Percentage of Participants With Study Medication Withdrawn Due to an Adverse Event</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Persistent Infection</measure>
    <time_frame>Up to Month 54 in the base study</time_frame>
    <description>Combined Incidence of HPV Type 31/33/45/52/58-related persistent infection as determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. Persistent infection was defined as infection detected in samples from &gt;=2 consecutive visits 6 months (+/-1 month visit window) or longer apart. Incidence was defined as the number of cases of persistent infection per 10,000 person-years of follow-up in a treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base Study: Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58</measure>
    <time_frame>4 weeks postdose 3</time_frame>
    <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">14840</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <condition>Genital Warts</condition>
  <condition>Human Papillomavirus Infection</condition>
  <arm_group>
    <arm_group_label>Base Study Part A: GARDASIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GARDASIL 0.5 mL injection in 3-dose regimen in the base study Part A. Participants in this arm who receive ≥1 dose of GARDASIL in base study Part A can enter the extension study and receive a 3-dose regimen of V503 at the dose administered in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Base Study Part A: V503 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V503 low dose, 0.5 mL injection in 3-dose regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Base Study Part A: V503 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V503 mid dose, 0.5 mL injection in 3-dose regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Base Study Part A: V503 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V503 high dose, 0.5 mL injection in 3-dose regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Base Study Part B: V503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V503 (dose to be selected after Part A is complete), 0.5 mL in 3-dose regimen. Approximately 150 participants in this arm will receive a fourth dose of V503 in the extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Base Study Part B: GARDASIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GARDASIL 0.5 mL injection in 3-dose regimen in the base study. Participants in this arm who receive ≥1 dose of GARDASIL in the base study can enter the extension study and receive a 3-dose regimen of V503 at the dose administered in Part B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: GARDASIL</intervention_name>
    <description>GARDASIL (quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen</description>
    <arm_group_label>Base Study Part A: GARDASIL</arm_group_label>
    <arm_group_label>Base Study Part B: GARDASIL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental: V503</intervention_name>
    <description>V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen</description>
    <arm_group_label>Base Study Part A: V503 Low Dose</arm_group_label>
    <arm_group_label>Base Study Part A: V503 Mid Dose</arm_group_label>
    <arm_group_label>Base Study Part A: V503 High Dose</arm_group_label>
    <arm_group_label>Base Study Part B: V503</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female between 16- to 26-years-old

          -  Has never had Pap testing or has only had normal Pap test results

          -  For the immune memory substudy in the extension (Cohort 1): was randomized to V503 in
             Part B of the base study and was in the per-protocol immunogenicity population for ≥1
             HPV type

          -  For the 3-dose V503 vaccination substudy in the extension (Cohort 2): was randomized
             to GARDASIL in either Part A or Part B of the base study and received ≥1 dose of
             GARDASIL

        Exclusion Criteria:

          -  History of an abnormal cervical biopsy result

          -  History of a positive test for HPV

          -  History of external genital/vaginal warts

          -  Currently a user of any illegal drugs or an alcohol abuser

          -  History of severe allergic reaction that required medical attention

          -  Are pregnant

          -  Received marketed HPV vaccine or participated in an HPV trial

          -  Currently enrolled in a clinical trial

          -  Currently has or has a history of certain medical conditions or is currently taking
             or has taken certain medications (details will be discussed at the time of consent.)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother. 2015;11(6):1313-22. doi: 10.1080/21645515.2015.1012010.</citation>
    <PMID>25912208</PMID>
  </results_reference>
  <results_reference>
    <citation>Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study.. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044.</citation>
    <PMID>25693011</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials. 2015 Feb;12(1):84-90. doi: 10.1177/1740774514552110. Epub 2014 Oct 1.</citation>
    <PMID>25278227</PMID>
  </results_reference>
  <results_reference>
    <citation>Luxembourg A, Bautista O, Moeller E, Ritter M, Chen J. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp Clin Trials. 2015 May;42:18-25. doi: 10.1016/j.cct.2015.02.009. Epub 2015 Mar 3.</citation>
    <PMID>25749310</PMID>
  </results_reference>
  <results_reference>
    <citation>Pitisuttithum P, Velicer C, Luxembourg A. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Rev Vaccines. 2015;14(11):1405-19. doi: 10.1586/14760584.2015.1089174. Epub 2015 Sep 14. Review.</citation>
    <PMID>26366475</PMID>
  </results_reference>
  <results_reference>
    <citation>Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016 Aug;138(2). pii: e20154387. doi: 10.1542/peds.2015-4387.</citation>
    <PMID>27422279</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 22, 2016</lastchanged_date>
  <firstreceived_date>October 12, 2007</firstreceived_date>
  <firstreceived_results_date>December 12, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participant flow covers from study start to a data cutoff date of 10 March 2014</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low-dose V503</title>
          <description>V503 (9-Valent Human Papillomavirus [HPV] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
        </group>
        <group group_id="P2">
          <title>Mid-dose V503</title>
          <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
        </group>
        <group group_id="P3">
          <title>High-dose V503</title>
          <description>V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
        </group>
        <group group_id="P4">
          <title>Gardasil</title>
          <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="7106"/>
                <participants group_id="P3" count="310"/>
                <participants group_id="P4" count="7109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 3 Vaccinations</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="6928"/>
                <participants group_id="P3" count="297"/>
                <participants group_id="P4" count="6934"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="295">Follow-up was up to 7 months</participants>
                <participants group_id="P2" count="5854">Follow-up was up to 54 months</participants>
                <participants group_id="P3" count="296">Follow-up was up to 7 months</participants>
                <participants group_id="P4" count="5887">Follow-up was up to 54 months</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="1252"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="1222"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="749"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="701"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="482"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="503"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-dose V503</title>
          <description>V503 (9-Valent Human Papillomavirus [HPV] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
        </group>
        <group group_id="B2">
          <title>Mid-dose V503</title>
          <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
        </group>
        <group group_id="B3">
          <title>High-dose V503</title>
          <description>V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
        </group>
        <group group_id="B4">
          <title>Gardasil</title>
          <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="315"/>
            <count group_id="B2" value="7106"/>
            <count group_id="B3" value="310"/>
            <count group_id="B4" value="7109"/>
            <count group_id="B5" value="14840"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.7" spread="2.4"/>
                    <measurement group_id="B2" value="21.9" spread="2.5"/>
                    <measurement group_id="B3" value="21.9" spread="2.4"/>
                    <measurement group_id="B4" value="21.8" spread="2.5"/>
                    <measurement group_id="B5" value="21.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="7106"/>
                    <measurement group_id="B3" value="310"/>
                    <measurement group_id="B4" value="7109"/>
                    <measurement group_id="B5" value="14840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis)</title>
        <description>HPV Type 31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer were determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. This outcome measure reports data based on the protocol-specified plan of conducting hypothesis testing when at least 30 cases had accumulated. The cutoff date for this analysis was 10 April 2013. Disease incidence was defined as the number of primary efficacy cases per 10,000 person-years of follow-up in a treatment arm.</description>
        <time_frame>From Day 1 until &gt;=30 cases accumulate, up to Month 54 in the base study</time_frame>
        <population>The Per-protocol Efficacy population included all participants who received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable day ranges, were seronegative at Day 1 and PCR negative at Day 1 through Day 7 to the relevant HPV types, and had at least 1 follow-up visit following Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis)</title>
          <description>HPV Type 31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer were determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. This outcome measure reports data based on the protocol-specified plan of conducting hypothesis testing when at least 30 cases had accumulated. The cutoff date for this analysis was 10 April 2013. Disease incidence was defined as the number of primary efficacy cases per 10,000 person-years of follow-up in a treatment arm.</description>
          <population>The Per-protocol Efficacy population included all participants who received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable day ranges, were seronegative at Day 1 and PCR negative at Day 1 through Day 7 to the relevant HPV types, and had at least 1 follow-up visit following Month 7.</population>
          <units>Cases per 10,000 person-years follow-up</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6016"/>
                <count group_id="O2" value="6017"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Exact test, 1-sided</method>
            <param_type>Vaccine efficacy</param_type>
            <param_value>96.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.9</ci_lower_limit>
            <ci_upper_limit>99.8</ci_upper_limit>
            <estimate_desc>Vaccine efficacy = 100 * [1 - (incidence rate with V503 / incidence rate with Gardasil)]. The pre-specified success criterion was a lower bound of the 95% confidence interval of observed efficacy of &gt;25%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (End-of-study Update)</title>
        <description>HPV Type 31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer were determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. This outcome measure reports cumulative study data through 10 March 2014. Disease incidence was defined as the number of primary efficacy cases per 10,000 person-years of follow-up in a treatment arm.</description>
        <time_frame>Up to Month 54 in the base study</time_frame>
        <population>The Per-protocol Efficacy population included all participants who received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable day ranges, were seronegative at Day 1 and PCR negative at Day 1 through Day 7 to the relevant HPV types, and had at least 1 follow-up visit following Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (End-of-study Update)</title>
          <description>HPV Type 31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer were determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. This outcome measure reports cumulative study data through 10 March 2014. Disease incidence was defined as the number of primary efficacy cases per 10,000 person-years of follow-up in a treatment arm.</description>
          <population>The Per-protocol Efficacy population included all participants who received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable day ranges, were seronegative at Day 1 and PCR negative at Day 1 through Day 7 to the relevant HPV types, and had at least 1 follow-up visit following Month 7.</population>
          <units>Cases per 10,000 person-years follow-up</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6016"/>
                <count group_id="O2" value="6017"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>97.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.0</ci_lower_limit>
            <ci_upper_limit>99.9</ci_upper_limit>
            <estimate_desc>Vaccine efficacy = 100 * [1 - (incidence rate with V503 / incidence rate with Gardasil)]. The pre-specified success criterion was a lower bound of the 95% confidence interval of observed efficacy of &gt;25%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18/31/33/45/52/58</title>
        <description>Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. Statistical analysis was performed only for HPV types contained in both vaccines.</description>
        <time_frame>4 weeks postdose 3 in the base study</time_frame>
        <population>The Per-protocol Immunogenicity population included all participants who were not protocol violators, received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable ranges, were seronegative at Day 1 and PCR negative from Day 1- Month 7 for the relevant HPV types, and had a Month 7 serum sample collected within an acceptable range</population>
        <group_list>
          <group group_id="O1">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18/31/33/45/52/58</title>
          <description>Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. Statistical analysis was performed only for HPV types contained in both vaccines.</description>
          <population>The Per-protocol Immunogenicity population included all participants who were not protocol violators, received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable ranges, were seronegative at Day 1 and PCR negative from Day 1- Month 7 for the relevant HPV types, and had a Month 7 serum sample collected within an acceptable range</population>
          <units>milli Merck U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6792"/>
                <count group_id="O2" value="6795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6 (n=3993, 3975)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="893.1" lower_limit="871.7" upper_limit="915.1"/>
                    <measurement group_id="O2" value="875.2" lower_limit="854.2" upper_limit="896.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11 (n=3995, 3982)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="666.3" lower_limit="649.6" upper_limit="683.4"/>
                    <measurement group_id="O2" value="830.0" lower_limit="809.2" upper_limit="851.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16 (n=4032, 4062)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3131.1" lower_limit="3057.1" upper_limit="3206.9"/>
                    <measurement group_id="O2" value="3156.6" lower_limit="3082.3" upper_limit="3232.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18 (n=4539, 4541)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="804.6" lower_limit="782.7" upper_limit="827.1"/>
                    <measurement group_id="O2" value="678.7" lower_limit="660.2" upper_limit="697.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31 (n=4466, 4377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="658.4" lower_limit="636.7" upper_limit="680.9"/>
                    <measurement group_id="O2" value="9.7" lower_limit="9.4" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 33 (n=4702, 4691)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.9" lower_limit="405.6" upper_limit="426.4"/>
                    <measurement group_id="O2" value="NA">The GMT value was &lt;4 milli Merck U/mL</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45 (n=4792, 4750)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.8" lower_limit="246.2" upper_limit="259.6"/>
                    <measurement group_id="O2" value="NA">The GMT value was &lt;3 milli Merck U/mL</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52 (n=4455, 4335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.7" lower_limit="371.6" upper_limit="388.0"/>
                    <measurement group_id="O2" value="NA">The GMT value was &lt;3 milli Merck U/mL</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58 (n=4486, 4446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="482.5" lower_limit="469.9" upper_limit="495.3"/>
                    <measurement group_id="O2" value="NA">The GMT value was &lt;4 milli Merck U/mL</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 6</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided confidence interval (CI) of the GMT ratio was &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 11</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided CI of the GMT ratio was &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 16</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided CI of the GMT ratio was &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 18</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided CI of the GMT ratio was &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extension Study: Geometric Mean Titers to HPV Types 6/11/16/18/31/33/45/52/58</title>
        <time_frame>Day 7 and Day 28 postdose 4 in the extension study</time_frame>
        <posting_date>07/2017</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With One or More Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
        <time_frame>Up to Month 7 (low- and high-dose V503) or up to Month 54 (mid-dose V503 and Gardasil)</time_frame>
        <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O2">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O3">
            <title>High-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O4">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With One or More Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
          <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="7071"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="7078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6"/>
                    <measurement group_id="O2" value="94.2"/>
                    <measurement group_id="O3" value="92.8"/>
                    <measurement group_id="O4" value="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With One or More Injection-site Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.</description>
        <time_frame>Up to Day 5 after any vaccination</time_frame>
        <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O2">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O3">
            <title>High-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O4">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With One or More Injection-site Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.</description>
          <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="7071"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="7078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7"/>
                    <measurement group_id="O2" value="90.7"/>
                    <measurement group_id="O3" value="90.5"/>
                    <measurement group_id="O4" value="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With One or More Non-injection-site (Systemic) Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.</description>
        <time_frame>Up to Day 15 after any vaccination</time_frame>
        <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O2">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O3">
            <title>High-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O4">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With One or More Non-injection-site (Systemic) Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.</description>
          <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="7071"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="7078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="51.1"/>
                    <measurement group_id="O4" value="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With One or More Vaccine-related Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. An AE that is judged by the investigator to be “definitely related,” “probably related,” or “possibly related” to the study drug is defined as a vaccine-related AE.</description>
        <time_frame>Up to Month 7 (low- and high-dose V503) or up to Month 54 (mid-dose V503 and Gardasil)</time_frame>
        <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O2">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O3">
            <title>High-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O4">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With One or More Vaccine-related Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. An AE that is judged by the investigator to be “definitely related,” “probably related,” or “possibly related” to the study drug is defined as a vaccine-related AE.</description>
          <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="7071"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="7078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="92.2"/>
                    <measurement group_id="O3" value="92.8"/>
                    <measurement group_id="O4" value="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Base Study: Percentage of Participants With Study Medication Withdrawn Due to an Adverse Event</title>
        <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event.</description>
        <time_frame>Up to Month 6</time_frame>
        <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O2">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O3">
            <title>High-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
          </group>
          <group group_id="O4">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants With Study Medication Withdrawn Due to an Adverse Event</title>
          <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event.</description>
          <population>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="7071"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="7078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Persistent Infection</title>
        <description>Combined Incidence of HPV Type 31/33/45/52/58-related persistent infection as determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. Persistent infection was defined as infection detected in samples from &gt;=2 consecutive visits 6 months (+/-1 month visit window) or longer apart. Incidence was defined as the number of cases of persistent infection per 10,000 person-years of follow-up in a treatment arm.</description>
        <time_frame>Up to Month 54 in the base study</time_frame>
        <population>The Per-protocol Efficacy population included all participants who received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable day ranges, were seronegative at Day 1 and PCR negative at Day 1 through Day 7 to the relevant HPV types, and had at least 1 follow-up visit following Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Persistent Infection</title>
          <description>Combined Incidence of HPV Type 31/33/45/52/58-related persistent infection as determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. Persistent infection was defined as infection detected in samples from &gt;=2 consecutive visits 6 months (+/-1 month visit window) or longer apart. Incidence was defined as the number of cases of persistent infection per 10,000 person-years of follow-up in a treatment arm.</description>
          <population>The Per-protocol Efficacy population included all participants who received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable day ranges, were seronegative at Day 1 and PCR negative at Day 1 through Day 7 to the relevant HPV types, and had at least 1 follow-up visit following Month 7.</population>
          <units>Cases per 10,000 person-years follow-up</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5941"/>
                <count group_id="O2" value="5955"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="538.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>96.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.6</ci_lower_limit>
            <ci_upper_limit>97.1</ci_upper_limit>
            <estimate_desc>Vaccine efficacy = 100 * [1 - (incidence rate with V503 / incidence rate with Gardasil)]. The pre-specified success criterion was a lower bound of the 95% confidence interval of observed efficacy of &gt;25%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Base Study: Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58</title>
        <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.</description>
        <time_frame>4 weeks postdose 3</time_frame>
        <population>The Per-protocol Immunogenicity population included all participants who were not protocol violators, received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable ranges, were seronegative at Day 1 and PCR negative from Day 1 - Month 7 for the relevant HPV types, and had a Month 7 serum sample collected within an acceptable range</population>
        <group_list>
          <group group_id="O1">
            <title>Mid-dose V503</title>
            <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Gardasil</title>
            <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Base Study: Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58</title>
          <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.</description>
          <population>The Per-protocol Immunogenicity population included all participants who were not protocol violators, received all 3 vaccinations of mid-dose V503 or Gardasil within acceptable ranges, were seronegative at Day 1 and PCR negative from Day 1 - Month 7 for the relevant HPV types, and had a Month 7 serum sample collected within an acceptable range</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6792"/>
                <count group_id="O2" value="6795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6 (n=3993, 3975)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.8" lower_limit="99.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11 (n=3995, 3982)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.9" upper_limit="100"/>
                    <measurement group_id="O2" value="99.9" lower_limit="99.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16 (n=4032, 4062)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18 (n=4539, 4541)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.7" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.7" lower_limit="99.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31 (n=4466, 4377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="50.1" lower_limit="48.7" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 33 (n=4702, 4691)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="99.5" upper_limit="99.9"/>
                    <measurement group_id="O2" value="12.7" lower_limit="11.8" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45 (n=4792, 4750)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="99.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="9.2" lower_limit="8.4" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52 (n=4455, 4335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.2" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58 (n=4486, 4446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="20.4" lower_limit="19.2" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (AEs): up to Month 7 (low- and high-dose V503) or up to Month 54 (mid-dose V503 and Gardasil); Other adverse events: up to Day 15 after any vaccination for systemic AEs; up to Day 5 after any vaccination for injection-site AEs</time_frame>
      <desc>The analysis population included all participants who received &gt;=1 vaccination and had safety follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low-Dose V503</title>
          <description>V503 (9-Valent HPV Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
        </group>
        <group group_id="E2">
          <title>Mid-dose V503</title>
          <description>V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. A subset of participants will receive a fourth V503 mid-dose vaccination in the extension study.</description>
        </group>
        <group group_id="E3">
          <title>High-dose V503</title>
          <description>V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study Part A.</description>
        </group>
        <group group_id="E4">
          <title>Gardasil</title>
          <description>Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study Part A or Part B. Participants will be offered the V503 mid-dose 3-dose regimen in the extension study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="7071"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="305"/>
                <counts group_id="E4" subjects_affected="184" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Postural orthostatic tachycardia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cleft lip and palate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Diverticulitis Meckel's</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Omental infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to vaccine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Haemorrhagic fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Post abortion infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bladder injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Ependymoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Leukaemic infiltration brain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Malignant palate neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Nasal cavity cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Respiratory papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Benign intracranial hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Orthostatic intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="7071"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E4" events="28" subjects_affected="26" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cervix dystocia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Foetal malposition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Foetal malpresentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Labour complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Prolonged labour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Uterine contractions during pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia and bulimia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Anorexia nervosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Cervix haemorrhage uterine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Fallopian tube cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="76" subjects_affected="73" subjects_at_risk="7071"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E4" events="53" subjects_affected="53" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7071"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="278" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="6551" subjects_at_risk="7071"/>
                <counts group_id="E3" subjects_affected="280" subjects_at_risk="305"/>
                <counts group_id="E4" subjects_affected="6268" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="310"/>
                <counts group_id="E2" events="617" subjects_affected="513" subjects_at_risk="7071"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="305"/>
                <counts group_id="E4" events="551" subjects_affected="459" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="157" subjects_affected="100" subjects_at_risk="310"/>
                <counts group_id="E2" events="3597" subjects_affected="2411" subjects_at_risk="7071"/>
                <counts group_id="E3" events="140" subjects_affected="91" subjects_at_risk="305"/>
                <counts group_id="E4" events="2564" subjects_affected="1810" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="684" subjects_affected="267" subjects_at_risk="310"/>
                <counts group_id="E2" events="15383" subjects_affected="6360" subjects_at_risk="7071"/>
                <counts group_id="E3" events="672" subjects_affected="273" subjects_at_risk="305"/>
                <counts group_id="E4" events="13001" subjects_affected="5911" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="310"/>
                <counts group_id="E2" events="494" subjects_affected="389" subjects_at_risk="7071"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="305"/>
                <counts group_id="E4" events="341" subjects_affected="282" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="154" subjects_affected="100" subjects_at_risk="310"/>
                <counts group_id="E2" events="4527" subjects_affected="2836" subjects_at_risk="7071"/>
                <counts group_id="E3" events="168" subjects_affected="103" subjects_at_risk="305"/>
                <counts group_id="E4" events="2988" subjects_affected="2035" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="310"/>
                <counts group_id="E2" events="563" subjects_affected="469" subjects_at_risk="7071"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="305"/>
                <counts group_id="E4" events="550" subjects_affected="463" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="310"/>
                <counts group_id="E2" events="343" subjects_affected="312" subjects_at_risk="7071"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="305"/>
                <counts group_id="E4" events="314" subjects_affected="296" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="310"/>
                <counts group_id="E2" events="412" subjects_affected="376" subjects_at_risk="7071"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="305"/>
                <counts group_id="E4" events="420" subjects_affected="389" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="310"/>
                <counts group_id="E2" events="405" subjects_affected="346" subjects_at_risk="7071"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="305"/>
                <counts group_id="E4" events="368" subjects_affected="307" subjects_at_risk="7078"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="100" subjects_affected="65" subjects_at_risk="310"/>
                <counts group_id="E2" events="3071" subjects_affected="1879" subjects_at_risk="7071"/>
                <counts group_id="E3" events="106" subjects_affected="66" subjects_at_risk="305"/>
                <counts group_id="E4" events="2788" subjects_affected="1756" subjects_at_risk="7078"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
